Genoprotective effects of royal jelly (RJ) treatments against doxorubicin (DXR), a potent genotoxic chemotherapeutic compound in human lymphocytes were investigated using the sister chromatid exchange (SCE) assay, and their molecular mechanisms were examined by Western blot. Results showed that RJ pretreatments at 0.005 and 0.05 mg/mL significantly decreased DXR-induced SCE levels by 1.2-fold (p<0.05), compared to DXR treatment alone. Co-treatment of RJ (5 mg/mL) with DXR (0.2 µg/mL) increased the ratios of BCL2/BAX (1.5-fold), NRF2/BAX (1.3-fold), and hTERT/BAX (1.1-fold) compared to the DXR alone, suggesting its power in enhancing cell survival, antioxidative potentials, and longevity over cell death. The study suggested that RJ protected human cells from DXR-induced genotoxicity, possibly mediated through anti-apoptotic, anti-oxidative, and anti-aging properties of RJ. However, lower doses of RJ co-treatments enhanced DXR toxicity. Further, in vivo molecular study is required to validate this in vitro study.
Carcinogenesis is a multi-step process, comprising of various changes at genomic levels. The reduction of genetic damage is crucial for protecting cells against cancer. Royal Jelly (RJ) is a nutritious product secreted from the hypopharyngeal gland of nurse bees to feed the queen throughout her life and has various biological and pharmacological activities. Townsend et al. 1960 reported that RJ and its fatty acid, 10-hydroxy-2-decenoic acid inhibited the development of mouse leukemia and ascitic tumors cell lines [1] . Salizar-Olivo et.al. 2005 noted that RJ was cytotoxic against Hela carcinoma cells [2] while enhancing rat hepatocyte proliferation [3] . RJ also showed hepatoprotection against carbon tetrachloride in rats [4] , neuroprotection against neurotoxic tartrazine on rat pups' brains [5] , nephroprotection against cisplatin in mice [6] , and cardioprotection against paclitaxel in rats [7] . However, genoprotective studies and insights into its molecular mechanisms in human cells are limited. Doxorubicin (DXR) is a potent genotoxic chemotherapeutic compound, which acts as a DNA topoisomerase inhibitor and generates free radical damage [8] . Our study is focused on elucidating the antigenotoxic activity of RJ treatments against DXR in human lymphocytes in vitro. Sister chromatid exchange (SCE) assay, a standard protocol for determining genotoxicity [8b] , was conducted to evaluate the genoprotective potential of RJ (0.0005-5 mg/mL) against DXR-induced DNA damage in human lymphocytes in vitro. Effects on cell proliferation and cell cycle progression were also determined. RJ (0.0005-5 mg/mL) co-treatments with DXR were performed in human lymphocytes in vitro to evaluate their effects on specific gene expressions: C-MYC, hTERT, BCL2, BAX, NRF2, HO-1, cyclin E and cyclin B. These pivotal regulatory proteins are essential, responsible for cell proliferation, longevity, cell survival, cell apoptosis, antioxidative response and cell cycle progression. C-Myc (cellular myelocytomatosis), a transcriptional factor, controls cell proliferation. It activates various regulatory gene expressions including hTERT, a catalytic subunit of human telomerase reverse transcriptase [9] . h-TERT regulates telomere length involving cell senescence and immortality [10] . BCL2 (B-cell lymphoma 2), an antiapoptotic protein, promotes cell survival. BAX (BCL2 associated X protein), a pro-apoptotic protein, induces cell death [11] . NRF2 (nuclear factor erythroid 2 related factor 2) controls gene expression of antioxidative response [12] such as HO-1 (heme oxygenase). HO-1 is an inducible enzyme response to oxidative stress [13] . Cyclin E and cyclin B are cell cycle regulators. Cyclin E controls cell cycle transition from G1 to S phases, and cyclin B controls from G2 to M phases.
Our previous study demonstrated that RJ treatment at the lowest dose (0.0005 mg/mL) in human lymphocytes prolonged lifespan through hTERT activation while RJ at the highest dose (5 mg/mL) inhibited cell survival, cell proliferation and an antioxidative enzyme but activated an antioxidative response through NRF2 and maintained telomeres [14] . To further evaluate the effects of RJ in combination with DXR in human lymphocytes, we assessed the levels of those regulatory proteins and expressed them as ratios over BAX: BCL2/BAX, cMyc/BAX, hTERT/BAX, NRF2/BAX, and HO-1/BAX. Since BCL2/BAX has been used as a rheostat ratio known to reflect life or death [15] , we expected those consecutive ratios to represent health status of the treated cells better than individual protein levels alone. We hypothesized that the ratios would increase if RJ protected cells from DXR-induced DNA damage, resulting in enhanced cell survival, cell proliferation, longevity, and antioxidative response.
Composition profile of RJ sample: As shown in our earlier report [14] , the purchased Thai RJ had pH 4.0 with 65 g% moisture, 2.5 g% lipids, 2.2 g% proteins, 0.2 g% fiber, no ash, and 32 g% carbohydrates. Total phenolic acid was 1.8+0.5 mg Gallic acid equivalent/g, and total flavonoids were 0.9+0.1 mg Rutin equivalent/g. 10-Hydroxy-2-decenoic acid, ferulic acid, and sinapic acid were 8 mg/g, 2.5 μg/g, and 0.7 μg/g RJ, respectively. In addition, there was no significant difference of mitotic index or proliferation index induced by RJ pretreatments compared to the DXR treatment alone (Table 1 ). Further analysis of the effect of RJ pretreatments on each phase of the cell cycle (Figure 2 ), demonstrated that all RJ pretreatments increased cell cycle progression (higher MII than MI cells), while DXR treatment alone slightly delayed cell cycle (less MII than MI cells). The 2%DMSO pretreatment, however, noticeably delayed cell cycle. Cell viability of royal jelly co-treatments with doxorubicin in human lymphocytes detected by MTS tetrazolium assay: As shown in Table 2 , DXR treatment decreased cell viability by 50% compared to the negative, RPMI control. RJ co-treatments at 0.0005 and 5 mg/mL increased cell viability by approximately 10% compared to that of DXR treated cells. No statistically significant difference was observed. Effects of various concentrations of royal jelly on cell cycle regulation: As shown in Figure 3a , cyclin E and cyclin B had similar expression levels in the RPMI control (0.03-fold compared to actin). On the other hand, DXR treatment decreased the levels of cyclin E by 0.9-fold while markedly decreasing cyclin B by 0.3-fold ( Figure 3b ). Compared to the DXR treatment, RJ co-treatments at 0.005 and 0.05 mg/mL highly enhanced cyclin E at approximately 1.3-fold and 1.5-fold, while decreasing cyclin B 0.7-fold and 0.3-fold, respectively. RJ co-treatment at the highest dose (5 mg/mL) maintained cyclin E (1-fold) but decreased cyclin B (0.6-fold). On the contrary, 1% V/V DMSO co-treatment maintained cyclin E but markedly increased cyclin B (3.4-fold). NRF2, and decreased the levels of BAX (0.9-fold), BCL2 (0.8-fold), and HO-1 (0.6-fold). Results suggest that DXR treatment induced cell death more than cell survival and used up antioxidative enzyme HO-1.
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However, cells still maintained telomere length and kept proliferating. DMSO co-treatment markedly decreased HO-1 (0.2-fold), h-TERT (0.7-fold), and C-MYC (0.9-fold), maintained BCL2, BAX, and slightly increased NRF2 (1.1-fold). This result indicates that DMSO possibly enhanced DXR-induced oxidative damage and used up antioxidative enzyme HO-1, reduced longevity while slightly activating antioxidative response, NRF2.
RJ co-treatments at all doses increased hTERT (1.3-1.7-folds), BCL2 (1.2-2.1-folds) (except at the lowest dose) and BAX (1.4-1.8-folds) (except at the highest dose), compared to those of DXR treatment alone. They had an overall dose-dependent increase trend of NRF2 (0.8 to 1.3-folds) but had a dose-dependent decrease of c-MYC (1.6 to1.1-folds) and HO-1 (0.6 to 0.3-folds). Both BCL2 and BAX levels increased especially at the active cell cycle progression 82 Natural Product Communications Vol. 13 (1) 2018 Jenkhetkan et al.
highest dose enhanced cell survival, antioxidative response, and maintenance of telomere over cell death and therefore induced health protection against DXR. On the contrary, RJ co-treatments at the lower doses especially at 0.0005 mg/mL diminished cell survival, antioxidative response, longevity, cell proliferation and antioxidative enzyme HO-1, demonstrating its intensifying DXR toxicity. Therefore, beneficial or harmful effects of RJ cotreatments depend on its dosage. DMSO co-treatment decreased HO-1/BAX (0.3-fold), hTERT/BAX (0.5-fold), c-MYC/BAX (0.6-fold) and slightly increased BCL2/BAX and NRF2/BAX (1.05-fold). The DMSO solvent possibly had little additional effect on reduction of HO-1/BAX, hTERT/BAX, and c-MYC/BAX but did not show any major effects on RJ activity.
Our data reveal that DXR (0.1 µg/mL) significantly increased SCE level by 2.2-fold compared to RPMI control in human lymphocytes. Pretreatment with RJ protected human cells from DXR-induced SCE level by 1.2-fold (p<0.05). RJ co-treatment at the highest dose of 5 mg/mL increased BCL2/BAX, NRF2/BAX, and hTERT/BAX ratios, which demonstrated its protective potential against DXR toxicity. Induction of these essential regulatory proteins demonstrated its effectiveness in enhancing cell survival, antioxidative response, and cell longevity. In addition, it decreased HO-1/BAX, possibly related to immediate antioxidative enzyme response against free radical damage induced by the DXR, resulting in HO-1 depletion. Lastly, the RJ co-treatment decreased c-MYC/BAX ratio, possibly related to delaying cell proliferation and allowing more time for damaged cells to be repaired. This result corresponded with its decreasing cyclin B level, which possibly delayed the G2/M transition. This molecular study supported previous reports of RJ benefits. [18] . Our study also verified that a specific dose of RJ protected human cells from DXR-induced toxicity and increased the BCL2/BAX ratio. Additionally, RJ co-treatment used up HO-1 and enhanced NRF2, relating to the power of its antioxidative response in protecting cells from DXR-induced oxidative damage. Previous reports also demonstrated that the antioxidant activity of RJ protected testis from diabetes-induced impairment [19] and cisplatin-induced oxidative damage in rats [20] . In addition, RJ protected rats from paclitaxel-induced cardiotoxicity as shown by reduction of creatine kinase (CK-BM), and pathological injuries [7] . Therefore, RJ might protect against DXR-induced cardiotoxicity, which is a common side effect of DXR as well.
However, our study also demonstrated that RJ co-treatments at lower doses enhanced DXR-induced toxicity in human lymphocytes. Their BCL2/BAX, HO-1/BAX, c-MYC/BAX, hTERT/BAX, and NRF2/BAX ratios were lower than those of the DXR treatment alone. Few studies have reported on RJ toxicity. ElAidy et.al. 2015 noted that RJ induced lung inflammation in mouse conalbumin-induced asthma model [21] .
In conclusion, our study clarified the genoprotective effects of RJ against DXR in human lymphocytes in vitro. Its protective mechanisms possibly mediate through an increase of BCL2/BAX ratio for cell survival, increase in hTERT/BAX for enhancing longevity, and increase in NRF2/BAX for amplifying antioxidative response.
Nevertheless, its protective effects remain dose dependent. The improper dosage of RJ can enhance toxicity. Therefore, usage of RJ needs careful consideration. Further studies of RJ in conjunction with other genotoxicants are needed to verify its effectiveness. In vivo molecular study is also required to validate the optimum and safe doses of RJ.
Experimental
Analysis of the composition profile of royal jelly: Frozen RJ was purchased from an apiary company certified by the Ministry of Industry, Thailand. Carbohydrate, protein, ash and moisture contents in RJ were measured using AOAC methods [22] . Lipid content was determined using Soxhlet extraction with diethyl ether as a solvent. Total phenolic and total flavonoid contents were analyzed by Folin-Ciocalteu's reagent and aluminum chloride colorimetric assay, respectively [23] . 10-Hydroxy-2-decenoic acid, ferulic acid, and sinapic acid levels were examined by quantitative high-performance liquid chromatography (HPLC) [24, 25] .
Antigenotoxic studies of royal jelly against doxorubicin by sister chromatid exchange assay: Fresh blood samples for all experiments were obtained by venipuncture from 6 healthy volunteers, aged 25-35 years, with no recent exposure to radiation or drugs. This study was approved by our institutional ethics committee (MTU-EC-DS-2-067/56). Lymphocyte-enriched buffy coat (from 0.8 mL whole blood) was cultured in 5 mL culture medium containing PRMI 1640 (Hyclone, USA), fetal bovine serum (Hyclone, USA), autologous plasma, penicillinstreptomycin (Seromed, Germany), phytohemagglutinin (Seromed, Germany) and L-glutamine (Hyclone, USA) using standard blood culture conditions as previously described [26] . At 24 h after initiation of the culture, the lymphocyte cultures were centrifuged for packed cells, and the supernatant medium was removed and saved for reuse. The remaining lymphocytes were treated with RJ at concentrations of 0.0005, 0.005, 0.05, 0.5 and 5 mg/mL dissolved in 2% V/V dimethylsulfoxide (DMSO) in RPMI 1640 culture medium at 37°C for 2 h. Then, the treated cells were washed and further treated with 0.1 µg/mL DXR (Pharmacia and Upjohn, USA) for 2 h at 37°C. After treatment, the lymphocyte cultures were centrifuged for packed cells, and the supernatant medium discarded. The treated lymphocytes continued to be cultured at 37°C in the dark with the previously saved medium, and bromodeoxyuridine (BrdU) solution was added to the final concentration at 5 mM. For positive control, the lymphocytes were pretreated with RPMI for 2 h, washed and treated with 0.1 µg/mL DXR for 2 h. For solvent control, cells were pretreated with 2%V/V DMSO for 2 h, washed, and treated with 0.1 µg/mL DXR for 2 h. For the negative control, cells were cultured only with RPMI 1640 medium.
The cells were harvested at 96 h after initiation because of cell cycle delay. Slides were prepared and stained using the fluorescent plus Giemsa technique as previously described [26b]. Twenty-five cells per dose per experiment showing the second metaphase-staining pattern were scored from the coded slides for frequencies of sister chromatid exchange (SCE). The proliferation index and mitotic index were also evaluated for their cytotoxicity. The mitotic index was determined by the number of all mitotic cells/1,000 cells. The proliferation index was determined as (MI+2MII+3MIII)/100 cells, where MI is the number of metaphase cells from the first cell cycle (homogeneously-stained chromatids), MII is the number of metaphase cells from the second cell cycle (heterogeneously-stained chromatids), and MIII is the number of metaphase cells from the third cell cycle (mixed homogenously-stained and heterogeneouslystained chromatids). Two to three independent experiments were performed for each concentration of the treated compound.
Genoprotective effects of royal jelly treatments against doxorubicin Natural Product Communications Vol. 13 (1) 
83
Statistical analysis: A square root transformation of the SCE data was required to stabilize the variances, according to the procedures of Whorton et al. 1984 [27] . The frequency of transformed SCE was expressed as a square root of SCE. Dunnett's t-test was performed to analyze the difference between the means of the treated groups and the means of the control groups using the transformed data. Data are shown as mean + standard error of mean.
Cell viability of RJ co-treatments with DXR for 24 h in human lymphocytes detected by MTS tetrazolium assay: Human lymphocytes were isolated by using LymphoprepTM (STEMCELL Technologies, Canada). Isolated human lymphocytes were cultured in RPMI medium containing fetal calf serum, L-glutamine, phytohaemagglutinin, penicillin-streptomycin in a 5% CO 2 incubator at 37C for 24 h. Then, cells were treated with various concentrations of RJ (0.0005, 0.005, 0.05, 0.5 and 5 mg/mL) and 0.2 µg/mL DXR for 24 h. RPMI 1640 and 1% V/V DMSO were used as negative controls. DXR (0.2 µg/mL) was used as a positive control.
All treated cells were used to determine the percentage of cell viability by MTS assay and specific gene expressions by Western blot analysis. The CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) Kit (Promega, USA) was used to determine cell viability. Following the manufacturer's instruction, twenty microlitres of the MTS tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reagent) was added to each culture well containing treated cells in 100 µL of the medium, incubated at 37°C for 2 h in a humidified 5% CO 2 . The MTS was reduced by NADH or NADPH, produced by metabolically active cells. The formazan products were formed and measured by the absorbance at 490 nm with a PowerWave™ XS microplate spectrophotometer (BioTek, USA). The percentage of cell viability was expressed as a percentage relative to the untreated control cells.
Specific gene expression levels detected by Western blot: All treated human lymphocytes were harvested and lysed with Ripa lysis buffer containing protease inhibitor cocktail set I (Merck Millipore, USA). Protein samples were boiled and separated on SDS-polyacrylamide denaturing gels, followed by blotting onto nitrocellulose membranes (GE Healthcare, USA) and blocking with the Odyssey blocking buffer (LI-COR, USA).
After that, membranes were probed with corresponding rabbit primary antibodies: anti-BCL2, anti-BAX, anti-c-MYC, anti-HO-1, and anti-cyclin B (Cell Signaling, USA); anti-hTERT, anti-NRF2, and anti-cyclin E (Merck Millipore, USA).
Rabbit anti-β-actin polyclonal antibody (Cell Signaling, USA) was used as an internal control. Membranes were then washed, and incubated with LI-COR IRDye 680 mouse anti-rabbit antibody. The protein bands were visualized using Odyssey Fc Imager.
